Brukinsa

Approximately 600 people are affected by the form of non-Hodgkin lymphoma every year in the UK

The new formulation would allow blood cancer patients to halve their daily pill intake

The new formulation has been authorised for all five indications covered by the original capsule version

Approximately 2,600 cases of the blood cancer are diagnosed in the UK every year

More than two-thirds of patients have advanced or metastatic disease at the time of diagnosis

Approximately 15,000 new cases of follicular lymphoma are diagnosed in the US every year

The BTK inhibitor was approved in the US earlier this year and had its patent issued last week

Approximately 3,800 people in the UK are diagnosed with chronic lymphocytic leukaemia each year

The BTK inhibitor demonstrated better results than Imbruvica, a standard of care treatment in CLL

The BTK inhibitor is now approved for chronic lymphocytic leukaemia and marginal zone lymphoma

The drug showed better results than Imbruvica, a current standard of care treatment

The BTK inhibitor was also granted an additional year of marketing protection